Vivitrol drug maker Alkermes, Inc. ALKS announced last night that it received FDA approval for an expanded indication that includes "the prevention of relapse to opioid dependence," Jefferies & Company reports.
“We are currently projecting CY11 sales of $40M,” Jefferies & Company writes. “The product has an ~75% gross margin. If one assumes the product was break-even at $25M, then the incremental $11M in gross profit should drop to the bottom line and contribute ~$0.12 to CY11 earnings (assuming no taxes).”
Alkermes currently trades for $15.68.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in